SB202190 (FHPI)

Name: SB202190 (FHPI)
Brand: Selleck Chemicals
SKU: S1077
Rating: 5 (89 reviews)

For research use only.

Catalog No.S1077

89 publications

CAS No. 152121-30-7

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1. SB202190 significantly suppresses Erastin‐dependent ferroptosis.

Selleck's SB202190 (FHPI) has been cited by 89 publications

Cancer Cell, 2019, 35(5):798-815

PubMed: 31031016 ( click the link to review the publication )

Cancer Discov, 2018, 8(1):74-93

PubMed: 28923912 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(6):577-582

PubMed: 28459450 ( click the link to review the publication )

Nat Biotechnol, 2016, 34(11):1161-1167

PubMed: 27723727 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(7):428-36

PubMed: 23685672 ( click the link to review the publication )

Redox Biol, 2020, 28:101445

PubMed: 32037305 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):771

PubMed: 32943609 ( click the link to review the publication )

Cells, 2020, 13;9(5) pii: E1209

PubMed: 32414111 ( click the link to review the publication )

Cells, 2020, 28;9(4) pii: E822

PubMed: 32231153 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Cell Discov, 2020, 6:35

PubMed: 32550000 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(5):3203-3216

PubMed: 32053272 ( click the link to review the publication )

Eur J Immunol, 2020, 10.1002/eji.201948363

PubMed: 32022930 ( click the link to review the publication )

Sci Rep, 2020,

PubMed: 32884042 ( click the link to review the publication )

Front Pharmacol, 2020, 11:758

PubMed: 32523533 ( click the link to review the publication )

Chem Biol Interact, 2020, 317:108944

PubMed: 31935364 ( click the link to review the publication )

Int J Environ Health Res, 2020, 10.1080/09603123.2020.1739236

PubMed: 32191530 ( click the link to review the publication )

Ann Surg Oncol, 2020, 10.1245/s10434-020-08790-2

PubMed: 32632882 ( click the link to review the publication )

J Thorac Dis, 2020, 12(7):3764-3773

PubMed: 32802455 ( click the link to review the publication )

J Exp Med, 2020, 217(2)

PubMed: 31753849 ( click the link to review the publication )

J Dev Biol, 2020, 8(3):E12

PubMed: 32660129 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0963-y

PubMed: 32606358 ( click the link to review the publication )

Cell Prolif, 2020, e12869

PubMed: 32597573 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2020, 10(4):779-796

PubMed: 32561494 ( click the link to review the publication )
Mol Cell, 2019, 76(6):965-980

PubMed: 31588023 ( click the link to review the publication )

Theranostics, 2019, 9(13):3879-3902

PubMed: 31281520 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):718

PubMed: 31558705 ( click the link to review the publication )

Cells, 2019, 8(7)

PubMed: 31248002 ( click the link to review the publication )

Cells, 2019, 8(9)

PubMed: 31461951 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.29305

PubMed: 31612516 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(4)

PubMed: 30781441 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31117181 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 370(2):219-230

PubMed: 31189728 ( click the link to review the publication )

Life Sci, 2019, 231:116550

PubMed: 31185235 ( click the link to review the publication )

J Biol Eng, 2019, 13:82

PubMed: 31709009 ( click the link to review the publication )

J Biol Eng, 2019, 13:36

PubMed: 31061676 ( click the link to review the publication )

Mol Cell, 2018, 71(1):117-128

PubMed: 30008317 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 29595474 ( click the link to review the publication )

Sci Signal, 2018,

PubMed: 29511118 ( click the link to review the publication )

EBioMedicine, 2018, 36:497-507

PubMed: 30190207 ( click the link to review the publication )

Front Immunol, 2018, 9:1051

PubMed: 29896191 ( click the link to review the publication )

Cancer Immunol Immunother, 2018, 67(2):271-283

PubMed: 29090321 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:9793845

PubMed: 30693038 ( click the link to review the publication )

Am J Transl Res, 2018, 10(8):2555-2566

PubMed: 30210692 ( click the link to review the publication )

Infect Immun, 2018, 22;86(9):e00233-18

PubMed: 29986890 ( click the link to review the publication )
Eur J Pharmacol, 2018, 838:129-137

PubMed: 30196111 ( click the link to review the publication )

Toxicon, 2018, 155:1-8

PubMed: 30290166 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2018, 5(3):333-352

PubMed: 29552622 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(1):38-45

PubMed: 27820799 ( click the link to review the publication )

Biomaterials, 2017, 128:44-55

PubMed: 28288348 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

Free Radic Biol Med, 2017, 104:280-297

PubMed: 28131902 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 323:44-52

PubMed: 28341536 ( click the link to review the publication )

Int J Mol Med, 2017, 39(1):217-222

PubMed: 27878250 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 5(2):113-130

PubMed: 29693040 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 4(1):165-182

PubMed: 29204504 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2242

PubMed: 27297582 ( click the link to review the publication )

Int J Mol Sci, 2016,

PubMed: 27782092 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2016, 303:79-89

PubMed: 27174766 ( click the link to review the publication )

J Cancer, 2016, 7(8):900-9

PubMed: 27313779 ( click the link to review the publication )

J Diabetes Res, 2016, 2016:9073037

PubMed: 27635403 ( click the link to review the publication )

Oncol Rep, 2016, 35(5):3009-17

PubMed: 26986870 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Neurochem Res, 2016, 41(8):1969-81

PubMed: 27068033 ( click the link to review the publication )

Mol Med Rep, 2016, 14(2):1430-8

PubMed: 27278862 ( click the link to review the publication )

Oncotarget, 2016, 7(25):37407-37419

PubMed: 27270648 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10269-78

PubMed: 26831669 ( click the link to review the publication )
Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Inflamm Bowel Dis, 2015, 21(3):496-506

PubMed: 25647156 ( click the link to review the publication )

Cell Transplant, 2015, 24(3):573-88

PubMed: 25654487 ( click the link to review the publication )

Nat Commun, 2014, 5:3479

PubMed: 24632940 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Chem Res Toxicol, 2014, 27(9):1575-85

PubMed: 25148906 ( click the link to review the publication )

BMC Cancer, 2014, 14:325

PubMed: ( click the link to review the publication )

Life Sci, 2014, 108(2):63-70

PubMed: 24857982 ( click the link to review the publication )

Int Immunopharmacol, 2014, 24(1): 50-58

PubMed: 25479727 ( click the link to review the publication )

J Cell Biochem, 2014, 115(5):874-88

PubMed: 24375433 ( click the link to review the publication )

Cell Transplant, 2014, 23(4-5):641-56

PubMed: 24816456 ( click the link to review the publication )

Mol Biosyst, 2014, 10(3):605-12

PubMed: 24413303 ( click the link to review the publication )

Mol Cell Biochem, 2014, 397(1-2):131-8

PubMed: 25138701 ( click the link to review the publication )

Anticancer Agents Med Chem, 2014, 14(8):1154-60

PubMed: 24934165 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

J Biol Chem, 2010, 285(43):32824-33

PubMed: 20729213 ( click the link to review the publication )

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description

Targets

Ferroptosis ^[11] ()	p38α ^[1] (Cell-free assay)	p38β ^[1] (Cell-free assay)
	50 nM	100 nM

In vitro

SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB202190 by itself is sufficient to induce cell death in Jurkat and HeLa cells through activation of CPP32-like caspases, which can be blocked by expression of bcl-2. SB202190-induced apoptosis is attenuated by p38β but augmented by p38α. ^[2] SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. ^[3] SB 202190 treatment inhibits the expression of albumin-induced proinflammatory (monocyte chemoattractant protein-1) and transforming growth factor (TGF)-beta1-induced profibrotic (procollagen-Ialpha1) genes over 50% in renal tubular cells (normal rat kidney-52E). ^[4] SB 202190 treatment induces phosphorylation of JNK in a dose- and time- dependent manner in A549 cells, induces phosphorylation of ATF-2 transcription factor, and increases AP-1 DNA binding. ^[6] SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190. ^[7]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT-116	M2HWcWZ2dmO2aX;uJGF{e2G7	M1XLdlI2KM7:TR?=	NH3KWJc{OCCvaX6=	M1XqUmROW00EoB?=	NYr1VodH[XS2ZX71ZZRmeyC2aHWgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO\|aX;uJI9nKGiERD2yJIlvKHKnc4DvcpNqfmVidH:gSGE>	NY\HWWFvOjZ{MkOyOVE>
MDA-MB-231	MVTGeY5kfGmxbjDBd5NigQ>?	MYiyJO69VQ>?	M1H4RVI1KGh?		NImyNI5t\XO\|ZX7ld{BES0x{IHnu[JVkfGmxbjDifUBVVkcQsR?=	MYOyOlExODh2OB?=
rBMSCs	MVrGeY5kfGmxbjDBd5NigQ>?	NVfh[Zg4OTBizszN	NInFbVMzNjViaB?=		M1fifoRmeHKnc4Pld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFXST{BidmRicEO4	MlvnNlYxPTN{Nk[=
MG63	MXTGeY5kfGmxbjDBd5NigQ>?	NI\1RZAyOC9{MD:zNEDPxE1?	MXyyOEBp		MXvzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgcIV3\Wxib3[gdIhwe3Cqb4L5cIF1\WRicEO4JIlv\HWlZXSgZpkhS2SFbEKgbY4h[SClb37j[Y51emG2aX;uJE1l\XCnbnTlcpQhdWGwbnXy	NVy1V2RZOjV7OUizNVI>
MG63	NVHXR3hrSXCxcITvd4l{KEG\|c3H5	NWS0dXJDOTBxMkCvN\|Ah\|ryP	NHLaNGwzPCCq		NGrBdY5{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnZDD0bIUh[XCxcITvd4l{KHKjdHWgc4YhVUd4MzDpcoR2[2WmIHL5JGNlS2x{	NXLySZJQOjV7OUizNVI>
HTSMCs	NGP0eppHfW6ldHnvckBCe3OjeR?=	MVOwMlEwOS9zMDFOwG0>	NXzYWY45OSCq		NUTacZNLcW6qaXLpeIVlKEORUl2tNk1qdmS3Y3XkJGhQNTFicILveIVqdiCuZY\lcJMh[W6mIH3SUmEh\XiycnXzd4lwdg>?	NVfrTWZ2OjV7MkG0OlQ>
MIA PaCa-2	NXjmblNoTnWwY4Tpc44hSXO\|YYm=	MWCyNOKh\|ryP	MX[yOEBp		NY\JWotremWmdXPl[EBt[WO2YYTlJIFk[3WvdXzheIlwdiCrbjDjc41jcW6jdHnvckB4cXSqIHLveIghOi2GRzDhcoQhTC2jbHzvd4XDqA>?	M{KwU\|I2QDh6NEi5
MIA PaCa-2	M4\yfmZ2dmO2aX;uJGF{e2G7	NI\1b5IzOMLizszN	Mn\NNlQhcA>?		M3jwd5Jme3WudIOgbY4h[SCvb3Tld5QhcW6qaXLpeIlwdiCxZjDITWYuOc7zIIDyc5RmcW5iYXPjeY12dGG2aX;u	NXnhOZhVOjV6OEi0PFk>
BxPC-3	M1vT[WZ2dmO2aX;uJGF{e2G7	MWeyNOKh\|ryP	NYjSdHdHOjRiaB?=		MmTJdoV{fWy2czDpckBiKG2xZHXzeEBqdmirYnn0bY9vKG:oIFjJSk0y\|rFicILveIVqdiCjY3P1cZVt[XSrb36=	MYCyOVg5QDR6OR?=
AsPC-1	NGXhXJZHfW6ldHnvckBCe3OjeR?=	MYGyNOKh\|ryP	NHnlW4QzPCCq		M4[xO5Jme3WudIOgbY4h[SCvb3Tld5QhcW6qaXLpeIlwdiCxZjDITWYuOc7zIIDyc5RmcW5iYXPjeY12dGG2aX;u	Ml33NlU5QDh2OEm=
MIA PaCa-2	NX7EN3JGTnWwY4Tpc44hSXO\|YYm=	NXf0T5RROjEEoN88US=>	NFPUfIYzPCCq		NYTnc3FR\W6qYX7j[ZMh[2ynYY\h[4Uhd2ZiUFHSVEB4cGWwIHPvcYJqdmWmIIfpeIgh\2y3Y3;z[UBidmGub3fz	NUjGVo91OjV6OEi0PFk>
MIA PaCa-2	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEG3V2YzOMLizszN	M4H1fVIhcA>?		MlXKd4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm	NUHzeJhJOjV6OEi0PFk>
BxPC-3	NYD3ZWp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXKyNOKh\|ryP	MofVNkBp		M2LjSZNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>?	M36wU\|I2QDh6NEi5
AsPC-1	MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\TNlDDqM7:TR?=	MkP6NkBp		Mo\Qd4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm	NWP0dVhWOjV6OEi0PFk>
HEY	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\RNlDDqM7:TR?=	MUCyJIg>		NISycIJ{\W6\|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V?	MUeyOVg5QDR6OR?=
OVCAR-3	M{ezUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rSVVIxyqEQvF2=	NICyWnUzKGh?		Mmm0d4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm	M1rWOFI2QDh6NEi5
SK-OV-3	Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHTNlDDqM7:TR?=	NV:0[m1XOiCq		M1K0SpNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>?	M3;wSlI2QDh6NEi5
MH7A	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mm[1NlQhcA>?		NVfINmJKemWrbn\vdoNmeyC2aHWgbY5pcWKrdH;yfUBm\m[nY4TzJI9nKFiDTh?=	M1PqdVI2QDZ{OU[2
MH7A	MmnURZBweHSxc3nzJGF{e2G7	MVuyOUDPxE1?	MYSyOEBp		NXj2R4kyemW4ZYLz[ZMh[2WubDDjfYNt\SCjcoLld5QhcW6mdXPl[EBjgSC[QV6gZY5lKGOjdYPl[EBieG:ydH;zbZMhd2ZiY3XscJMhfmmjIHHjeIl3[XSrb36gc4YhUk6N	MlzmNlU5PjJ7Nk[=
SCC25	NYHIeYJlTnWwY4Tpc44hSXO\|YYm=	MWOyNEDPxE1?	MYGyOEBp		Ml[5bY5kemWjc3XzJIF2fG:yaHHnfUBt\X[nbB?=	NHrPN\|gzPTh\|NESwNC=>
HaCaT	MnnoSpVv[3Srb36gRZN{[Xl?	NYjTelNoPSEEtV2=	MnnzNlQhcA>?		MXTpcohq[mm2czDJSm4u\|rNvaX7keYNm\CCFQ1yyNkBxem:mdXP0bY9vKGyndnXsdy=>	MlHWNlU5OzR\|NUO=
HaCaT	NV;yfIlnTnWwY4Tpc44hSXO\|YYm=	M3fSWlUhyrWP	M{HYcFI1KGh?		NGPGUJZqdmirYnn0d{BKTk5vzsGtbY5lfWOnZDDDR2wzOiCycn;keYN1cW:wIHzleoVtew>?	MmjTNlU5OzR\|NUO=
HPAEpiCs	MV3GeY5kfGmxbjDBd5NigQ>?	Mk\nNU8{NzFyIN88US=>	M3HRVlEhcA>?		M1Lx[pJm\HWlZYOgV\|FRNWmwZIXj[YQhUUODTT2xJJBzd3SnaX6gZY5lKG2UTlGg[ZhxemW\|c3nvckBidmRicILvcY91\XJiYXP0bZZqfHl?	MoPvNlU4OzR7MEC=
HPAEpiCs	MYLGeY5kfGmxbjDBd5NigQ>?	M4nLe\|EwOy9zMDFOwG0>	NXPI[5JsOSCq		MVvpcohq[mm2czDTNXAue3SrbYXsZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:wIDFCpC=>	NXHIRoNpOjV5M{S5NFA>
HPAEpiCs	NVvVdI9RTnWwY4Tpc44hSXO\|YYm=	Mn7VNU8{NzFyIN88US=>	NFL0[XoyKGh?		NFzoOItqdmirYnn0d{BUOVBidHnt[U1l\XCnbnTlcpRtgSC\|dHnteYxifGWmIHOtTpVvKHCqb4PwbI9zgWyjdHnvci=>	NYP4[JpWOjV5M{S5NFA>
K562	MXfGeY5kfGmxbjDBd5NigQ>?	NU\rT2I1OTEEoN88US=>	NITFSJgyyqCq	Mmj6SG1UVw>?	M3;aSolvcGmkaYTzJJF2cW6jY4LpcoUucW6mdXPl[EBxOzhiTVHQT{BxcG:\|cHjvdplt[XSrb36=	NYrJNXVmOjV4OESwOFM>
PANC-1	NXXye4FTTnWwY4Tpc44hSXO\|YYm=	NWryfllnOTBizszN	NF:xdocyKGh?		Mn3N[Y5p[W6lZYOgeIhmKGG3dH;wbIFocWNiZX\m[YN1yqB?	Mnf4NlU3OzJ{MkK=
BxPC-3	NHXS[2ZHfW6ldHnvckBCe3OjeR?=	M1nKfVExKM7:TR?=	M3rtWlEhcA>?		MnX5[Y5p[W6lZYOgeIhmKGG3dH;wbIFocWNiZX\m[YN1yqB?	MoH2NlU3OzJ{MkK=
K562	NFnxdVZHfW6ldHnvckBCe3OjeR?=	NEnwPGcxNjJ3LUGg{txO	NG\5SJkzPCCq		NFTKepV{fXCycnXzd4V{KHKnc4\ldoF1em:uLXnu[JVk\WRiSELBXEBxcG:\|cHjvdplt[XSrb36=	NXi3WW9rOjV4MUmzPVI>
THP-1	MUfGeY5kfGmxbjDBd5NigQ>?	NI\pUXA2KML3TR?=	NFHJcXMzKGh?		M3u1dpNq\26rZnnjZY51dHliYYT0[Y52[XSnczDz[YNz\XSrb36gc4YhUUxvMd8xJIlv\HWlZXSgZpkhOjeRSFPoc4wheGy3czDGV2wuOcLi	M1\qRlI2PTl6Nk[x
WB	MkTCSpVv[3Srb36gRZN{[Xl?	NE\4TIszOOLCid88UeKh	MlOwN\|DjiImvaX6=		NFW2OG9l\WO{ZXHz[ZMhfGinIFzQV{0hd3JiTGTBMYlv\HWlZXSgTWwuPiCjbnSgWG5HNc7zwrDwdo9lfWO2aX;u	MXKyOVU{ODZ6Mh?=
RAW 264.7	MkDpSpVv[3Srb36gRZN{[Xl?	NVjFNYRIOTEEoN88US=>	NGTmTWU{OOLCiX3pci=>		M2TTbYlv\HWlZYOgZ4hiemGldHXybZN1cWNidnHjeY9t[XSrb36gc4YhV0O\|wrC=	M3XNVlI2PDZzM{m5
RAW 264.7	M1PZNmZ2dmO2aX;uJGF{e2G7	M13LdVExyqEQvF2=	Mom1N\|DjiImvaX6=		NWm5e5Vp[XS2ZX71ZZRmeyC2aHWg[YZn\WO2czDv[kBQWEdib36gc5N1\W:lbHHzeEBz\XS{YXP0bY9v	NIKxR5UzPTR4MUO5PS=>
HaCaT	NFr0V4ZHfW6ldHnvckBCe3OjeR?=	MV60NOKh\|ryP	MWOzMVI1KGh?	NE[zbIZFVVOR	M2rtOJJm\HWlZYOgeIhmKGGlY4XteYxifGmxbjDv[kBbVy1z	MVWyOVQ{PTR6NR?=
H9c2	M{O2XmZ2dmO2aX;uJGF{e2G7	MVi1NOKh\|ryPwrC=	MX2xNkBp		NXu1PYF{emWmdXPld{BNTEhicnXs[YF{\SCjbnSgUW1RKGyxc4O=	NUPMZWRYOjV{NEW4NVg>
HSCs	NEDmRmxCeG:ydH;zbZMhSXO\|YYm=	Ml\iNlUh\|ryP	MXGyOOKhcA>?		MVXzbYdvcW[rY3HueIx6KGG2dHXueYF1\XNiVFetbY5lfWOnZDDhZ5RqfmG2ZXSgTHNEeyCjcH;weI9{cXN?	NHfQd\|gzPDl4MUm1NC=>
THP-1	NXPPcFEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHTVbHQ4OiCq	MknySG1UVw>?	M3jN[2lEPTB;ND63{txO	NXjUdmh2OjR6MUWwPFc>
MDDCs	NHvRcmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVfUWm86PzJiaB?=	M1;pUWROW09?	NFTDSWxKSzVyMj63{txO	NIPCU2MzPDhzNUC4Oy=>
MDDCs	MoXJSpVv[3Srb36gRZN{[Xl?	NUfj[Vh6OC1zNTFOwG0>	M{nvUlQ5KGh?	Mme2SG1UVw>?	NV;DOI44e3WycILld5NmeyCLRl6t{tEh[W6mIFnQMVExKHC{b3T1Z5Rqd28EoB?=	M4e4UlI1QDF3MEi3
MDDCs	MWPGeY5kfGmxbjDBd5NigQ>?	MXiwMVE2KM7:TR?=	NGP3Vm01QCCq	M33LRmROW09?	NYXZR3ZHcW6qaXLpeJMhVUmSLUHhMEBOUVBvMXKgZY5lKFKDTmTFV{Bxem:mdXP0bY9v	NYjHfnREOjR6MUWwPFc>
MDDCs	MVfGeY5kfGmxbjDBd5NigQ>?	NFrVSGwyOCEQvF2=	NYG5OYFwOy53IHi=	NIe5U4NFVVOR	NVHJfoF4[myxY3vzJGVDV1ZiR2CsJIJ2fCCwb4SgWnNXKEdibXXkbYF1\WRiZX70dpkhcW62bzDoeY1idiCPRFTDdy=>	M2DLSlI1QDF3MEi3
macrophages	NFTT[lNHfW6ldHnvckBCe3OjeR?=	MljINgKBkc7:TR?=	MoXDOE426oDLaB?=		NGLPNVlkd22ybHX0[Yx6KGmwaHnibZR{KE2WLVnJTU1qdmS3Y3XkJIFkfGm4YYTpc44hd2ZiTl[t{tpD	M3nvdFI1QDB6NkOz
PDL	MXjGeY5kfGmxbjDBd5NigQ>?	MnnGNlDDqM7:TdMg	M1vxNlMxKG2rbh?=	MWHEUXNQ	NYXlfmF4e2mpbnnmbYNidnSueTDpcohq[mm2czD0bIUhfGWwc3ns[UBnd3KlZT3t[YRq[XSnZDDCUXAuOiCneIDy[ZN{cW:w	MXeyOFU3OTB6MR?=
AGS	MXfGeY5kfGmxbjDBd5NigQ>?	NX\3cpJLPSEQvF2=	MlniN\|AhdWmw		M{LWcpN2eHC{ZYPz[ZPDqDFvaX7keYNm\CClYYPwZZNmNThiYX7kJINie3Cjc3WtN{Bi[3SrdnH0bY9v	M{TYfVI1PTR5OEe4
H520	MmjSSpVv[3Srb36gRZN{[Xl?	MXqxNOKhyrWP	MV[xJIg>	MX3EUXNQ	NGfqOpJl\WO{ZXHz[ZMhfGinIIDlcYV1emW6ZXStbY5lfWOnZDDNV2gzKG2UTlGgZY5lKHC{b4TlbY4hdGW4ZXzz	M3TXVlI1PTNyNEe1
H1703	MnfFSpVv[3Srb36gRZN{[Xl?	NHz4dYoyOMLiwsXN	NV2zbplvOSCq	NXXPfHRPTE2VTx?=	Mn7O[IVkemWjc3XzJJRp\SCyZX3leJJmgGWmLXnu[JVk\WRiTWPINkBuWk6DIHHu[EBxem:2ZXnuJIxmfmWucx?=	MkmwNlQ2OzB2N{W=
H520	NIrtVG5HfW6ldHnvckBCe3OjeR?=	NXv4Ro5VOTEEoNM1US=>	NE\tUXUyOiCq	MV3EUXNQ	NGXxOXRqdmirYnn0d{Bx\W2ndILlfIVlNWWuaXPpeIVlKE2VSEKgdJJwfGWrbjDzeIFjcWyrdIm=	MX:yOFU{ODR5NR?=
H1703	M1u2SmZ2dmO2aX;uJGF{e2G7	MnzKNVDDqML3TR?=	MXixNkBp	NI[5bGFFVVOR	NWHmd2lTcW6qaXLpeJMheGWvZYTy[Zhm\C2nbHnjbZRm\CCPU1iyJJBzd3SnaX6gd5Ri[mmuaYT5	NWC1fGEyOjR3M{C0O\|U>
H520	NXrySpJCTnWwY4Tpc44hSXO\|YYm=	MV[xNOKhyrWP	NGLoNJI3KGh?	NUnnd3p3TE2VTx?=	NU\rV3Zne2mpbnnmbYNidnSueTDpcoNz\WG\|ZYOgeIhmKGyndnXsd{Bw\iC3YnnxeYl1cW5vY3;ubpVo[XSnZDDNV2gzKGmwIIDlcYV1emW6ZXSteJJm[XSnZNMgZ4VtdCCuaX7l	NHHzco0zPDV\|MES3OS=>
H1703	MlfaSpVv[3Srb36gRZN{[Xl?	MYqxNOKhyrWP	M1;GUlYhcA>?	M1HOc2ROW09?	NGHFSlN{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhdGW4ZXzzJI9nKHWkaYH1bZRqdi2lb37qeYdifGWmIF3TTFIhcW5icHXt[ZRz\XinZD30doVifGWmwrDj[YxtKGyrbnW=	MYeyOFU{ODR5NR?=
MC3T3-E1	NF3zV4hHfW6ldHnvckBCe3OjeR?=	M2XIcFAvOy9\|L{OwJO69VQ>?	NGXqbWMyKGh?		MoD0ZZR1\W63YYTld{BVVkZvzsGtbY5lfWOnZDDNUXAuQSCneIDy[ZN{cW:wIHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{wrC=	MlvaNlQ2ODJ4OU[=
MC3T3-E1	NYDIPJNmTnWwY4Tpc44hSXO\|YYm=	NXm3eHh1OzBizszN	MYqxJIg>		MWrheJRmdnWjdHXzJHRPTi4QsT3zeIlufWyjdHXkJJA{QCCPQWDLJJBpd3OyaH;yfYxifGmxbh?=	Mn6zNlQ2ODJ4OU[=
HUVECs	NXfTN\|FiTnWwY4Tpc44hSXO\|YYm=	NHrFTmMyOMLiwsXN	MlTBNUBp		MlXobY5pcWKrdIOgWG5HNc7zLXnu[JVk\WRiQ2jDUFEheHKxZIXjeIlwdg>?	NVHNfZpoOjR2OEe5OlQ>
AGS	NGTXRW5HfW6ldHnvckBCe3OjeR?=	NHH6S2cyOMLiwsXN	M3fyT\|MxyqCvaX6=		MUnpcohq[mm2czDJUE0y\|rJvaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QA>?	M37zb\|I1PDd7Nkix
MKN-45	NVHleVNoTnWwY4Tpc44hSXO\|YYm=	Mm\UNVDDqML3TR?=	NEmz[mE{OMLibXnu		NH\T[phqdmirYnn0d{BKVC1zzsKtbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKHB\|OB?=	NETzbZEzPDR5OU[4NS=>
AGS	NVTvdohRTnWwY4Tpc44hSXO\|YYm=	M{DPWFExyqEEtV2=	MYOzNOKhdWmw		NYjzU4Vp[XS2ZX71ZZRmeyCLTD2x{tIucW6mdXPl[EBISSClZXzsJI1q\3KjdHnvckBidmRiaX72ZZNqd25?	M3nZ[VI1PDd7Nkix
MKN-45	MonVSpVv[3Srb36gRZN{[Xl?	NX3Dbo8yOTEEoNM1US=>	MV:zNOKhdWmw		MUDheJRmdnWjdHXzJGlNNTIQsj3pcoR2[2WmIFfBJINmdGxibXnndoF1cW:wIHHu[EBqdn[jc3nvci=>	M{XOb\|I1PDd7Nkix
AGS	NHLtfY9HfW6ldHnvckBCe3OjeR?=	MU[xNOKhyrWP	MmXHN\|DDqG2rbh?=		Mof1d4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiSXytNe6zNWmwZIXj[YQhVU2SMjDhcoQhVU2SOTDtVm5CKGW6cILld5Nqd25?	NUn2bY85OjR2N{m2PFE>
MKN-45	M2HNbGZ2dmO2aX;uJGF{e2G7	MYmxNOKhyrWP	Mk\TN\|DDqG2rbh?=		NInrSZV{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDJcE0y\|rJvaX7keYNm\CCPTWCyJIFv\CCPTWC5JI1TVkFiZYjwdoV{e2mxbh?=	M3m4VVI1PDd7Nkix
DCs	Mm\wSpVv[3Srb36gRZN{[Xl?	MWCyNOKh\|ryP	NWPuNIVkOcLiaB?=		NI\0PXhl\WO{ZXHz[ZMhUUxvMUKgdJJw\HWldHnvci=>	NWTCfpo{OjR2M{S2N\|Y>
HUVEC	MmHpSpVv[3Srb36gRZN{[Xl?	NIjq[oQzOCEQvH5CpC=>	MYK1JIg>	M{frUWROW09?	MnvZdoVlfWOnczDjfZRwc2mwZTDlfJBz\XO\|aX;uJIxmfmWuczDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?=	M2XCWlI1OTh7ME[y
A 549	NWm3OFF2TnWwY4Tpc44hSXO\|YYm=	NX7ZSmpFPTBizszN	MWOxJIg>		MYLk[YNz\WG\|ZYOgeIhmKGyndnXsJI9nKEmOLUlCpC=>	M3yxW\|I1OTd7Nki4
H520	MVHGeY5kfGmxbjDBd5NigQ>?	NH6wdZA2NzFyIN88US=>	MWGxJIg>	NETYc4FFVVOR	MoW3[IVkemWjc3XzJG1UUDJicILveIVqdiCjczD3[YxtKGG\|IH3SUmEhdGW4ZXzzJIlvKGenZnn0bY5q[i2neIDvd4VlKGOnbHy=	NUHvdVdROjRzM{i5NFM>
H1703	M{jlPGZ2dmO2aX;uJGF{e2G7	NIrOd\|c2NzFyIN88US=>	MoDlNUBp	MV\EUXNQ	MWHk[YNz\WG\|ZYOgUXNJOiCycn;0[YlvKGG\|IIflcIwh[XNibWLORUBt\X[nbIOgbY4h\2WoaYTpcoljNWW6cH;z[YQh[2WubB?=	M{\6SFI1OTN6OUCz
H520	MmnISpVv[3Srb36gRZN{[Xl?	NYfCOW1kOTEEoNM1US=>	NFjnT44yOiCq	M4PrPWROW09?	MlPV[IVkemWjc3XzJG1UUDJibWLORUBidmRicILveIVqdiC\|dHHibYxqfHliaX6g[4VncXSrbnniMZRz\WG2ZXSgUnNEVENiY3XscJM>	NXf3R\|lMOjRzM{i5NFM>
H1703	M3\yRmZ2dmO2aX;uJGF{e2G7	M{n0UVExyqEEtV2=	NX7HTmVyOTJiaB?=	NIr6emlFVVOR	NUPCS\|lX\GWlcnXhd4V{KE2VSEKgcXJPSSCjbnSgdJJwfGWrbjDzeIFjcWyrdImgbY4h\2WoaYTpcoljNXS{ZXH0[YQhVlOFTFOgZ4VtdHN?	M{HR[lI1OTN6OUCz
MCF-7	M1qwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILxbZIyOMLizszN	MmLZNlTDqGh?		NFvRVplqdmirYnn0d{B1cGViQ2KxNFgucW6mdXPl[EBk\WyuIHTlZZRp	M{\HeFI1OTJ6OEWz
HPAEpiCs	MXXGeY5kfGmxbjDBd5NigQ>?	M2DHXlAvOS9zL{GwJO69VQ>?	MWexJIg>		MojJbY5pcWKrdIOgWG5HNc7zLXnu[JVk\WRiY2DMRVLDqHC{b4TlbY4h[W6mIH3SUmEh\XiycnXzd4lwdg>?	MnPXNlQxPjlzNUi=
podocytes	MXPGeY5kfGmxbjDBd5NigQ>?	M1nHUlExyqEQvF2=	NFXqVmcyKGh?		MXHpcohq[mm2czDUS2bPujFvaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QE2DUFugZY5lKEW{a{GvNuKh	NVjvZ5hPOjRyM{[yNVI>
MCF-7	NFvlSZFHfW6ldHnvckBCe3OjeR?=	M3jtSVExyqEQvF2=	NYrlSWkzOSCq	NInxXo5FVVOR	MkXHdoVlfWOnczD0bIUhX0FvaX7keYNm\CCyaH;zdIhwenmuYYTl[EBxOzhiTVHQTy=>	MoDsNlQxOTlyOUC=
MCF-7	NXXRc45JTnWwY4Tpc44hSXO\|YYm=	NWPkWFRTOTEEoN88US=>	MlvFNlQhcA>?	MlexSG1UVw>?	NVL2NWZNcW6lcnXhd4V{KHSqZTDXRU1qdmS3Y3XkJIFxd3C2b4Ppdy=>	MXGyOFAyQTB7MB?=
HAPI	NEO5VmJHfW6ldHnvckBCe3OjeR?=	NULPeWJMOTBxMkCvOFDDqM7:TR?=	MmTBNUBp		M3X5TIlvcGmkaYTzJHRETERvaX7keYNm\CCyM{ivTm5MKE2DUFugdIhwe3Cqb4L5cIF1cW:w	MYKyN\|k3QTF{MB?=
HAPI	M3frO2Z2dmO2aX;uJGF{e2G7	MYOyNOKh\|ryPwrC=	NH6zfZcyKGh?	NIDpUHNFVVOR	NHvPeGNifHSnboXheIV{KFSFRFStbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKGmQT2OgZY5lKHC{b3T1Z5Rqd25?	NV3iWVVROjN7NkmxNlA>
HepG2	MlvrSpVv[3Srb36gRZN{[Xl?	M2L1SVM2OCCwTR?=	Mn7JNlQhcA>?		NFqwSJRqdmirYnn0d{B1cGViZHXneYVtcW5vaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QE2DUFu=	MU[yN\|k{OzF7OB?=
AGS	MWHGeY5kfGmxbjDBd5NigQ>?	MVOxNOKh\|ryP	M3rSNlMxKG2rbh?=		NGO5V5RqdmirYnn0d{Bk[XOyYYPlMVMh[WO2aY\heIlwdiCjbnSgbY5pcWKrdHnvckBw\iCHUlu=	NFS4cJIzOzh3MEm5OC=>
HepG2	MlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYCwMVUxKM7:TR?=	NXvPVlNGPDhiaB?=		NVXjcYpxcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MnXZNlM5ODd3MEi=
BEL7404	NUftWlBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV6wMVUxKM7:TR?=	NFXqNWY1QCCq		M1T0[IlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	MmroNlM5ODd3MEi=
HL7702	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LhXlAuPTBizszN	NVz3b3FIPDhiaB?=		MlrhbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	NEDPW4EzOzhyN{WwPC=>
HepG2	NEPLPVhHfW6ldHnvckBCe3OjeR?=	NGXL[XYxNTVyIN88US=>	M3jObFI1KGh?		NX25NFFwcW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDwN\|gh\G:5boP0doVidSCycn;0[YlveyCPQWDLRXBMOixiQWTGNkwhVVONMTDhcoQhUFOSMkegbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NG\wZnQzOzhyN{WwPC=>
BEAS-2B	NFXyZZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LzSVExKM7:TR?=	MnL2N\|AhdWmw		M33hTZJmfmW{c3XzJJRp\SCmZXPy[YF{\SCxZjDj[YxtKH[rYXLpcIl1gSCrbnT1Z4VlKGK7IFjDTS=>	NHPFRlIzOzd6NECzOC=>
BEAS-2B	MkT4R5l1d3SxeHn0fUBCe3OjeR?=	NF7VTWIyOCEQvF2=	MYezNEBucW5?		NHuwUVVqdmirYnn0[YQhfGinIHnuZ5Jm[XOnIHnuJGxFUCCjbnSgTWwuQCCneIDy[ZN{cW:w	MXOyN\|c5PDB\|NB?=
BEAS-2B	MnvDSpVv[3Srb36gRZN{[Xl?	MmrTNVAh\|ryP	M2nkSFMxKG2rbh?=		MXTk[YNz\WG\|ZYOgeIhmKGyndnXsd{Bw\iClYYPwZZNmNTNuIFLh[EBidmRiZnHz	M1XKN\|I{Pzh2MEO0
H9c2	MXzGeY5kfGmxbjDBd5NigQ>?	NVjE[ZJlOC5yMT:wMlEwOSEQvF2=	M{LiUVEhcA>?		NGOwN5lifHSnboXheIV{KFSQRj5OtU1qdmS3Y3XkJG1OWC17IHX4dJJme3Orb36sJI1TVkFibHX2[Yx{NCCjbnSgdJJwdW:2ZYKgZYN1cX[rdIm=	MXiyN\|c4PDJ3Mh?=
H9c2	M2PlR2Z2dmO2aX;uJGF{e2G7	NFX1dXYyKM7:TR?=	NYC3S5FyOSCq		Mmq0doVlfWOnczDUUmYu\|rFiZHny[YN1dHlic4TpcZVt[XSnZDDwN\|ghVUGSSzDwbI9{eGixconsZZRqd25?	M3HmUVI{Pzd2MkWy
U937	M1fGRmZ2dmO2aX;uJGF{e2G7	NVjmcmo6OTEEoN88UeKh	MVmxJIg>		MXzhZpJw\2G2ZYOgeIhmKGOjZn\lbY5mKGWoZnXjeEBwdiCPS2CtNUBidmRiUGCyRYPPuSCvUl7BJJRz[W6\|Y4LpdJRqd26jbDDs[ZZmdHN?	MWSyN\|cxPzN6Nx?=
U937	M3G3ZmZ2dmO2aX;uJGF{e2G7	MmXUNVDDqM7:TdMg	M1HvN\|EhcA>?		NYHIW5Ro[WK{b3fheIV{KGOjZn\lbY5mNWmwZIXj[YQhVUuSLUGg[I94di2{ZXf1cIF1cW:wIHHu[EBRWDKDY98xJJVxNXKnZ4XsZZRqd25?	NIjt[HAzOzdyN{O4Oy=>
U937	NWHQ[VBNTnWwY4Tpc44hSXO\|YYm=	NFzlfnkyOMLizszNxsA>	NUnJeIQ{OSCq		MmfXd5VxeHKnc4Pld{BkNUq3bjDhcoQhS1KHQjDwbI9{eGixconsZZRqd25iaX6gZ4Fn\mWrbnWteJJm[XSnZDDj[Yxte8Li	NFjoWG4zOzdyN{O4Oy=>
A549	NYH2NoE6TnWwY4Tpc44hSXO\|YYm=	MmfsNE4{NzNxM{Cg{txO	M1nTdlEhcA>?		NWDBVZFLe2mpbnnmbYNidnSueTDheJRmdnWjdHXzJGFVWM7\|Uz3t[YRq[XSnZDDDU3guOiCycn;0[YlvKGGwZDDtVm5CKGW6cILld5Nqd25iYX7kJJBzd22xdHXyJIFkfGm4aYT5xsA>	NUCwUpdVOjN4OEC2O\|Q>
A549	NES2OYtHfW6ldHnvckBCe3OjeR?=	MVWxNOKh\|ryPwrC=	MkLQNE0{OCCvaX6=		NYHDWHFUcW6qaXLpeJMhSVSSzsPTJIlv\HWlZXSgdFQzN3B2NDDNRXBMKGGwZDDwN\|ghVUGSSzDwbI9{eGixconsZZRqd25?	NHPrUJozOzZ6ME[3OC=>
A549	NHTDUJVHfW6ldHnvckBCe3OjeR?=	NEXMWG4yOMLizszNxsA>	MoH1NUBp		NFHtOGhqdmirYnn0d{BCXFEQs2OgbY5lfWOnZDDOSk3PwkJicE[1JJN2[nWwaYSgdIhwe3Cqb4L5cIF1cW:wIHHu[EBPTi4QulKgdJJwdW:2ZYKgZYN1cX[rdIm=	M3zYSlI{PjhyNke0
A549	NX3iU4ljTnWwY4Tpc44hSXO\|YYm=	NVPSeGJIOTEEoN88UeKh	MmjNNUBp		M{Oxb5Jm\HWlZYOgRXRR\|rOVLYP0bY12dGG2ZXSgZ3BNSTJicHjvd5Bpd3K7bHH0bY9vyqB?	NFXBXGgzOzZ6ME[3OC=>
A549	MXLGeY5kfGmxbjDBd5NigQ>?	NGDjd3YyOMLizszNxsA>	NUPRUWtpOSCq		MoPadoVlfWOnczDBWHDPu1NvZX7oZY5k\WRiZX76fY1ifGmlIHHjeIl3cXS7IH;mJINRVEF{wrC=	MVuyN\|Y5ODZ5NB?=
PC12	NI\pVplHfW6ldHnvckBCe3OjeR?=	NWXte3ZJOTBxMkCvOFAh\|ryP	M1nQ[lHDqGh?		MUHpcohq[mm2czDKUmsh[W6mIICzPC=>	MXuyN\|U5PDN3Nx?=
HK-2	MlLnRZBweHSxc3nzJGF{e2G7	NIn6UWczOMLizszN	MnfuNlQhcA>?		MkTtbY5pcWKrdIOgSXJMKGGwZDDwN\|hOSVCN	NXP0eWN4OjN3NEOxOVE>
H9c2	NXu3W2VVTnWwY4Tpc44hSXO\|YYm=	MXKxxsDPxE1?	NUjycpZ4OSCq		MWXy[YR2[2W\|IGTOSk3PuS2rbnT1Z4VlKE2PUD25JI1TVkFibHX2[Yx{KGGwZDDwdo9ud3SncjDhZ5Rqfmm2eR?=	M2jacFI{OzV\|Nkm5
H9c2	M3WxUGZ2dmO2aX;uJGF{e2G7	MmX6NeKh\|ryP	M{j6SFEhcA>?		MXry[YR2[2W\|IGTOSk3PuS2nbnjhcoNm\CCDUD2xJJBzd22xdHXyJIFkfGm4aYT5	MV:yN\|M2OzZ7OR?=
H1650	M4DZeWZ2dmO2aX;uJGF{e2G7	M370O\|ExyqEQvF5CpC=>	NHfYcJQyKGh?	NWLLWmJwTE2VTx?=	NWrZPZFG\GWlcnXhd4V{KGKxdHigdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdHNib3[gSXJESzFiaX6gdIFkdGm2YYjlcE1mgHCxc3XkxsBk\Wyucx?=	Mor4NlMzOjh4OU[=
H1703	MVLGeY5kfGmxbjDBd5NigQ>?	MYmxNOKh\|ryPwrC=	MW[xJIg>	NWjjS2JzTE2VTx?=	MUDk[YNz\WG\|ZYOgZo91cCCycn;0[YlvKGGwZDDtVm5CKGyndnXsd{Bw\iCHUlPDNUBqdiCyYXPsbZRigGWuLXX4dI9{\WUEoHPlcIx{	MYmyN\|IzQDZ7Nh?=
H1650	NHi4[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUKxNOKh\|ryPwrC=	MVmxJIg>	M372OGROW09?	MWPlcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6	M1uwV\|I{OjJ6Nkm2
H1703	NH;MW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVuweJZoOTEEoN88UeKh	M{PYRlEhcA>?	M3m4Z2ROW09?	MnPZ[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>?	NF\NTIczOzJ{OE[5Oi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	mTOR / p-S6K / S6K / p-S6 / p-AKT / p-MK2; PubMed: 26844273 EBioMedicine CRC cells were treated with 10 μM SB202190 for 2 h and analyzed for mTOR signaling and on-target inhibition of p38 by immunoblot. pJNK1 / pJNK2 / JNK1 / JNK2 ; PubMed: 18222647 Cell Signal A549 cells were treated with DMSO control or with 10 µM of SB202190 for 0.5, 1, 2, 3, 4, or 6 hours, and pJNK and unphosphorylated JNK were detected as described.	26844273 18222647
Immunofluorescence	p-p38 / MMP9; PubMed: 24479681 Mol Cancer Immunocytochemical staining and confocal microscopy confirmed that IL-1β increased activation of p38 (red), and MMP2 and MMP9 (green) expression in MKN-45 GA cells; these effects were blocked by p38 siRNA or the p38 inhibitor SB202190.	24479681
Growth inhibition assay	Cell viability ; PubMed: 26844273 EBioMedicine Top panel: CRC cells were treated with various concentrations of SB202190 for 48 h. Lower panel: CRC cells were treated with SB202190 at 10 μM for different times. Cell growth was measured by SRB assay (means ± s.d. in triplet, n = 3 in triplet).	26844273

In vivo

Inhibiting p38 by administration of SB 202190 inhibits PV IgG-induced blister formation in the passive transfer mouse model. ^[5] In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control. ^[8]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase assays: The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-³³P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-³³P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity.
Cell Research: ^[2]	- Collapse Cell lines: Jurkat, and HeLa Concentrations: Dissolved in DMSO, final concentrations ~50 μM Incubation Time: 24 hours Method: Cells are serum-starved and then treated with different concentration of SB 202190 for 24 hours. Cell viability is assayed by either trypan blue exclusion or propidium iodide exclusion followed by flow cytometry analysis. The apoptotic nuclei are visualized by H33258 staining. (Only for Reference)
Animal Research: ^[5]	- Collapse Animal Models: C57BL/6J mice injected i.d. with a sterile solution of either control IgG or PV IgG Dosages: 12.5 μg Administration: Administered via i.d. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	66 mg/mL (199.19 mM)
	Water	Insoluble
	Ethanol	'12 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%H2O For best results, use promptly after mixing.	8 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download SB202190 (FHPI) SDF

Molecular Weight	331.34
Formula	C₂₀H₁₄N₃OF
CAS No.	152121-30-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1=CC(=CC=C1C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Selective p38 MAPK Inhibitor

BIRB 796 (Doramapimod) : p38α-selective, Kd=0.1 nM.
Most Potent p38 MAPK Inhibitor

Skepinone-L ^New : p38α-MAPK, IC50=5 nM.
p38 MAPK Inhibitor in Clinical Trial

VX-702 : Phase II for Rheumatoid Arthritis.
Newest p38 MAPK Inhibitor

Skepinone-L ^New : Selective p38α-MAPK inhibitor with IC50 of 5 nM.

Related p38 MAPK Products

Pexmetinib (ARRY-614) ^New

Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.
SB239063 ^New

SB239063 is a potent and selective p38 MAPKα/β inhibitor with IC50 of 44 nM, showing no activity against the γ- and δ-kinase isoforms.
Ravoxertinib (GDC-0994) ^New

GDC-0994 is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
SB203580

SB203580 (RWJ 64809, PB 203580) is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM. SB203580 induces mitophagy and autophagy.

Features:First reported p38 inhibitor.
Doramapimod (BIRB 796)

Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with K_d of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.

Features:The first p38 MAPK inhibitor to be tested in a phase III clinical trial.
Ralimetinib (LY2228820)

Ralimetinib (LY2228820) is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2.
Losmapimod (GW856553X)

Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK inhibitor with pK_i of 8.1 and 7.6 for p38α and p38β, respectively. P38 MAPKs are involved in cell differentiation, apoptosis and autophagy. Phase 3.
PH-797804

PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM in a cell-free assay; 4-fold more selective versus p38β and does not inhibit JNK2. Phase 2.
VX-702

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Features:Highly selective, orally active inhibitor of p38 MAPK.
TAK-715

TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

SB202190 (FHPI)